Vansh Remedies Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vansh Remedies Pharmaceutical Export Portfolio Dataset — 2 Products, $400.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vansh Remedies — Pharmaceutical Exporter Profile (2026) | 2 Products, $400.0K Trade | TransData Nexus

Vansh Remedies

Indian Pharmaceutical Exporter · Antifungals Specialist · $400.0K Total Trade · DGFT Verified

Vansh Remedies is an Indian pharmaceutical exporter with a total trade value of $400.0K across 2 products in 2 therapeutic categories. Based on 8 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Nystatin ($250.0K), Tinidazole ($150.0K), .

Vansh Remedies — Export Portfolio & Destination Treemap

Vansh Remedies pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vansh Remedies? — Company Overview & Market Position

Vansh Remedies, established in 1991, is a pharmaceutical company headquartered in Vadodara, Gujarat, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Under the directorship of Mr. Jagdish Patel, Vansh Remedies has evolved from a modest beginning to a prominent position in Gujarat's contract manufacturing sector. Mr. Patel's leadership has been instrumental in the company's growth, combining business acumen with professional experience in the pharmaceutical field.

The company operates as a partnership, with Mr. Vinit Patel serving as a key partner. Vansh Remedies is registered under the Goods and Services Tax (GST) in Gujarat, with the GST number 24AAOFV5773H1ZN. The firm's revenue for the fiscal year 2022-2023 was approximately $400,000 USD, derived from eight export shipments. The product portfolio comprises two primary products across two therapeutic categories, with a concentration on antifungals and advanced antibiotics.

What Does Vansh Remedies Export? — Product Portfolio Analysis

Top Products by Export Value

1Nystatin$250.0K 2

Product Portfolio — Top 2 by Export Value

Vansh Remedies exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Nystatin	Antifungals	$250.0K	5	0.5%	15
2	Tinidazole	Advanced Antibiotics	$150.0K	3	0.8%	2

Vansh Remedies exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $400.0K. The top category is Antifungals (62.5% of portfolio), followed by Advanced Antibiotics (37.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vansh Remedies — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vansh Remedies operates manufacturing facilities in Vadodara, Gujarat, India. The plant specializes in the production of various pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the company's focus on contract manufacturing indicates a facility capable of handling diverse production requirements. The plant's specialization in these dosage forms underscores its commitment to quality and compliance with industry standards.

3Key Leadership

The leadership of Vansh Remedies is characterized by experienced professionals dedicated to the company's mission. Mr. Jagdish Patel serves as the Managing Director, providing visionary leadership and strategic direction. Mr. Vinit Patel is a key partner, contributing to the company's operations and growth. The leadership team's combined expertise in the pharmaceutical industry has been pivotal in establishing Vansh Remedies as a reputable manufacturer of pharmaceutical formulations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vansh Remedies Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vansh Remedies has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates shipments to various countries, suggesting compliance with international regulatory standards. For instance, in July 2024, Vansh Remedies exported pharmaceutical products to Uzbekistan, indicating adherence to the regulatory requirements of the destination country. While specific regulatory filings and approvals are not detailed, the company's export activities imply a commitment to meeting the standards of these markets.

2Emerging Markets

Vansh Remedies has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's export data reveals shipments to countries such as Ghana, Ivory Coast, Uzbekistan, Yemen, and Tanzania. For example, in October 2024, Vansh Remedies exported pharmaceutical products to Ghana, indicating market penetration in the region. Additionally, the company's product range includes suppositories, which are essential in various therapeutic areas, potentially facilitating access to these emerging markets.

3Geographic Strategy

Vansh Remedies — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Vansh Remedies' interactions with the U.S. Food and Drug Administration (FDA), such as facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's export data does not explicitly indicate shipments to the United States, suggesting that Vansh Remedies may not currently have a direct presence in the U.S. market. This absence could be due to various factors, including regulatory challenges or strategic business decisions. To enter the U.S. market, Vansh Remedies would need to comply with FDA regulations, which may involve obtaining necessary approvals and certifications.

2WHO & EU GMP

Information regarding Vansh Remedies' compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's export data indicates shipments to countries that may require such certifications, suggesting that Vansh Remedies may adhere to international quality standards. However, without explicit confirmation, it is advisable for potential partners and clients to verify the company's compliance with these certifications before engagement.

Vansh Remedies — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vansh Remedies operates in a competitive pharmaceutical industry, facing competition from both domestic and international manufacturers. While specific competitors are not identified in the available data, the company's focus on antifungals and advanced antibiotics places it in direct competition with other manufacturers specializing in these therapeutic categories. The company's export activities to emerging markets indicate a strategic approach to capturing market share in regions with growing pharmaceutical demand. To enhance its competitive position, Vansh Remedies may consider expanding its product portfolio and strengthening its presence in key markets.

2Key Differentiators

Vansh Remedies' key differentiators include its specialization in finished pharmaceutical formulations and a diverse product portfolio encompassing tablets, capsules, syrups, and injections. The company's focus on contract manufacturing in Gujarat has established it as a significant player in the region. Additionally, the inclusion of suppositories in its product range positions Vansh Remedies to meet specific therapeutic needs, potentially setting it apart from competitors.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Vansh Remedies as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vansh Remedies demonstrates a consistent track record in its export activities, with a total export value of $400,000 USD from eight shipments. The company's export data indicates transactions with various international buyers, including A & Z Life Science Ltd in Ghana and LLC Emir Pharma in Uzbekistan. For instance, in October 2024, Vansh Remedies exported pharmaceutical products to Ghana, and in July 2024, it shipped products to Uzbekistan. These consistent export activities reflect the company's reliability and commitment to meeting international demand.

2Certifications to Verify

Importers should verify the following certifications when considering products from Vansh Remedies:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facility complies with World Health Organization Good Manufacturing Practice (WHO-GMP) standards. This can be verified by checking the WHO's official list of prequalified manufacturers.

Frequently Asked Questions — Vansh Remedies

How many pharmaceutical products does Vansh Remedies export from India?

Vansh Remedies exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Nystatin ($250.0K), Tinidazole ($150.0K). Total export value is $400.0K.

What is Vansh Remedies's total pharmaceutical export value?

Vansh Remedies's total pharmaceutical export value is $400.0K, based on 8 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vansh Remedies cover?

Vansh Remedies exports across 2 therapeutic categories. The largest are Antifungals (62.5%, 1 products), Advanced Antibiotics (37.5%, 1 products).

Get Full Vansh Remedies Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.